San Diego, CA (PRWEB) May 23, 2013
Resource4thePeople is updating consumers today with news about what has become international litigation involving class-action lawsuits claiming that the popular birth control pills Yaz and Yasmin allegedly can cause blood-clotting problems that plaintiffs claim may be life threatening.
Justice Crane of the Ontario Superior Court of Justice has certified* a Yaz and Yasmin class action that contains similar allegations to those contained in American lawsuits consolidated in a class-action litigation before a federal judge in Illinois.**
Many of those cases are in the process of being settled, according to the manufacturer of the oral contraceptives.***
The Canadian national media outlet Global News reported* April 18, 2013 that "At the heart of the lawsuit are allegations that women across Canada were kept in the dark about the increased risk of blood clots, stroke, heart attack and gallbladder disease and other medical conditions they had from taking these contraceptives compared to other birth control pills."
"This important ruling for Canadian consumers comes as German pharmaceutical giant Bayer has publicly confirmed*** that it is continuing to settle similar cases that are progressing in U.S. federal courts,” said Resource4thePeople.
“As these cases are being settled we are receiving inquires from consumers about whether there may be an approaching deadline affecting their ability to join in this litigation.
“In response to the inquiries in the wake of these developments we are informing consumers that our national network of consumers will continue to offer free legal consultations to women who used Yaz or Yasmin and have allegedly suffered serious blood-clotting problems.”
Bayer has detailed in its annual report*** that it has settled about 4,800 of these lawsuits for over $1 billion and that there are over 13,000 claimants still seeking damages over side effects.
"As of February 12, 2013, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 4,800 claimants in the U.S. for a total amount of about US$1 billion," according to the annual report.
Bayer also said that it, "is only settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 3,200 of the pending unsettled claimants. Bayer will continue to consider the option of settling individual lawsuits in the U.S. on a case-by-case basis."
Bayer also has agreed** to pay up to $24 million to settle other lawsuits involving allegations over gall bladder side effects, according to the court files in the litigation.
These settlements are a different part of this consolidated litigation in U.S. District Court for the Southern District of Illinois in which plaintiffs claimed that they suffered gall bladder injuries because they used Yaz and Yasmin as contraceptives.**
Reuters News Service reported**** March 20, 2013 that the settlements also include Yaz and Yasmin cases in state courts in California, New Jersey and Pennsylvania.
"Under the agreement, Bayer will pay $2,000 to plaintiffs who suffered gallbladder injuries and $3,000 to individuals who had their gallbladders removed, according to the agreement," Reuters reported.
"The fact that there has been a significant increase in the number of Yaz and Yasmin blood-clotting lawsuits does not preclude other consumers who may have suffered such side effects from seeking compensation in their cases," said Resource4thePeople.
"We have been receiving numerous inquiries about whether it is too late to file a Yaz or Yasmin blood-clotting lawsuit. The answer is no. However every case is different and consumers are urged to contact our national team of attorneys to evaluate the legal options available."
Women who have filed Yaz and Yasmin blood-clotting lawsuits have claimed that they suffered blood clots, deep vein thrombosis, strokes and pulmonary embolisms as a result of their use of the contraceptives according to allegations contained in their lawsuits.**
Reuters in its report said that since 2009, Bayer has been hit by a wave of lawsuits claiming that the company knew or should have known of the health risks of the contraceptives and failed to warn users.
The federal court system has consolidated the thousands of Yaz and Yasmin blood-clotting lawsuits filed over claims of severe health problems into a multidistrict litigation.
Court records show that this special litigation is now in pre-trial evidence gathering and settlement talks before a federal judge who is overseeing thousands of such lawsuits in Illinois.**
Resource4thePeople also is alerting consumers to details of an April 10, 2012 Food and Drug Administration warning***** about Yaz and Yasmin blood-clotting side effects:
“The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.”
In its announcement the FDA said that “The revised drug labels (Beyaz, Safyral, Yasmin and Yaz) will report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone-containing products. The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.”
*Global News, 4/18/13; globalnews.ca/news/492236/ontario-judge-gives-green-light-to-yasmin-yaz-class-action-lawsuit/
** In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation MDL No. 2100, U.S. District Court, Southern District of Illinois